{"prompt": "['Novartis', 'Confidential', 'Page 37', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Class of medication', 'Minimum washout period prior to Screening (Visit', '1), Run-in (Visit 101) and Randomization (Visit', '201) 1,2,3', 'Intra-muscular depot corticosteroids', 'Must not be used within 3 months prior to Visit 101', '1 Treatment for recorded asthma exacerbation as defined in Section 6.4.5 is allowed ONLY until the asthma', 'exacerbation is resolved', '2', 'This table is not considered all-inclusive. Medications should be assessed for adherence to the indication and', 'other inclusion/exclusion criteria.', '3', 'These medications are also prohibited if administered for other indications.', '4 Study supplied rescue medication (salbutamol/albuterol rescue medication) provided at Visit 1 is allowed during', 'treatment but should be withheld for at least 6 hours prior to spirometry measurements at clinic visits. Clinic visits', 'may be rescheduled if rescue medication were taken less than 6 hours prior to the spirometry assessments.', 'Table 5-3 Prohibited Medications', 'Class of medication 1', 'Minimum cessation period prior to Run-in (Visit', '101)', 'Non-potassium sparing diuretics (unless', '7 days', 'administered as a fixed-dose combination with', 'a potassium conserving drug)', 'Non-selective systemic \u00df -blocking agents', '7 days', 'Cardiac anti-arrhythmics Class la', '7 days', 'Cardiac anti-arrhythmics Class III', '7 days, amiodarone 3 months', 'Other drugs with potential to significantly', '14 days or 5 half-lives, whichever is longer', 'prolong the QT interval (e.g. mizolastin and', 'terfenadine)', 'All antipsychotic agents (first, second and third', '14 days', 'generation, inclusive of atypical', 'antipsychotics). Combinations of antipsychotic', 'agents with antidepressants are prohibited', 'Serotonin Noradrenaline Reuptake Inhibitors', '14 days', '(SNRIs)', 'Monoamine-oxidase inhibitors', '14 days', 'Systemic anticholinergics', '7 days', 'Strong inhibitors of cytochrome P4503A e.g.', '7 days', 'ketoconazole', 'Tricyclic antidepressants (Please note that', '14 days', 'tetracyclics which are similar in class with', 'regards to drug interaction are also to be', 'excluded)', 'Other investigational drugs', '30 days or 5 half-lives, whichever is longer', 'Noradrenaline reuptake inhibitors', '7 days', 'Live attenuated vaccine', '30 days', '1 This table is not considered all-inclusive. Medications should be assessed for adherence to the indication and', 'other inclusion/exclusion criteria. Before starting wash-out of any of the listed prohibited medications in this table,', 'the investigator has to assess the benefit and risk carefully for each individual patient.Terminating any medication', 'solely for the purpose of meeting inclusion/exclusion criteria is not acceptable.', 'Table 5-4', 'Medications allowed under certain conditions', 'Class of medication', 'Condition']['Novartis', 'Confidential', 'Page 38', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Class of medication', 'Condition', 'Monoclonal antibody: IgE inhibitors (e.g.', 'Allowed if at stable dose for at least 3 months prior to', 'omalizumab), IL-5 inhibitors (e.g.', 'Visit 1', 'mepolizumab) **', 'Oral corticosteroids *', 'Allowed if at stable dose for at least 1 month prior to', 'Visit 1', 'Leukotriene Antagonist and leukotriene', 'Allowed if at stable dose for at least 1 month prior to', 'synthesis inhibitors **', 'Visit 1', 'Long-acting theophylline (methylxanthine)', 'If stabilized for at least 4 weeks prior to Visit 1 and', 'preparations **', 'throughout the trial. Not administered within 24 h', 'prior to study visit.', 'Short- acting theophylline (methylxanthine)**', 'If stabilized for at least 4 weeks prior to Visit 1 and', 'throughout the trial. Not administered within 12 h', 'prior to study visit.', 'Mucolytic agents not containing', 'If stabilized for at least 4 weeks prior to Visit 1 and', 'bronchodilators', 'throughout the trial', 'Systemic mast cell stabilizers e.g.', 'If stabilized for at least 4 weeks prior to Visit 1 and', 'cromoglycate, nedcromil, ketotifen', 'throughout the trial', 'Selective Serotonin Reuptake Inhibitors (must', 'Treatment regimen is stable for at least one month at', 'have no documented effect on any other', 'Visit 1', 'neurotransmitters or other biological', 'pathways. E.g. muscarinic pathway)', 'Inactivated influenza vaccination,', 'Not administered within 48 hours prior to a study visit', 'pneumococcal vaccination or any other', 'inactivated vaccine', 'Intra-nasal corticosteroids', 'Stable dose for at least 4 weeks prior to Visit 101.', 'In the case of as needed, provided an established', 'pattern of use has been documented.', 'Topical corticosteroids for the treatment of', 'In recommended doses and dosage regimens', 'eczema', 'Maintenance immunotherapy for allergies', 'Stable dose for at least 3 months prior to Visit 101', 'and throughout the trial.', '* Oral corticosteroids may be continued at a low stable dose after a course of steroid taper for', 'exacerbations at the discretion of the investigator.', '**During the treatment period, \"step up\" or add-on as well as \"step-down\" or de-escalation of', 'maintenance treatments are allowed, as described below and in Section.5.5.5 These treatments must', 'be used according to approved local labels.', 'If indicated for the treatment of an asthma exacerbation, any treatment deemed necessary by', 'the treating physician for the safety of the patient is allowed from the start of the asthma', 'exacerbation event (defined as per protocol Section 6.4.5) until the asthma exacerbation event', 'is resolved. If deemed necessary, the treating physician may \"step-up\" patient\\'s background', 'medication and/or add-on maintenance treatment options if they remain uncontrolled or', 'experience severe asthma exacerbations, refer to Section 5.5.5. Patients may NOT self-', 'medicate (other than administration of rescue medication) or adjust therapy without', 'permission/guidance from treating physician.']\n\n###\n\n", "completion": "END"}